Full Breakdown
FDA Rejects Disc Medicine's Bitopertin for Erythropoietic Protoporphyria
2/14/2026, 3:32:42 AM
Overview of the FDA Decision
On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting Disc Medicine's application for bitopertin, a treatment aimed at erythropoietic protoporphyria (EPP), a rare genetic blood disorder. This decision marks the first significant setback for a drug reviewed under the FDA's new Commissioner’s National Priority Voucher (CNPV) program, which was designed to expedite the approval process for drugs addressing national priorities.
Key Findings from the FDA
The FDA acknowledged that while Disc's clinical trials, specifically the AURORA and BEACON studies, demonstrated a significant reduction in protoporphyrin IX (PPIX) levels—a biomarker for EPP—the agency expressed concerns regarding the correlation between this biomarker and clinical outcomes related to sunlight exposure. The FDA's letter highlighted that the observed 40% reduction in PPIX levels was "relatively modest" and did not convincingly predict clinical benefits, such as improved tolerance to sunlight, which is critical for EPP patients.
Background on Erythropoietic Protoporphyria
EPP is characterized by the accumulation of protoporphyrin in the blood, leading to extreme sensitivity to sunlight and potentially severe pain. Patients often experience debilitating symptoms that restrict their daily activities, making effective treatments essential. Bitopertin was developed to inhibit glycine transporter type 1, aiming to reduce PPIX accumulation and alleviate symptoms.
Disc Medicine's Response and Future Plans
In response to the FDA's rejection, Disc Medicine's CEO, John Quisel, stated that the company remains committed to addressing the FDA's concerns and is optimistic about the ongoing Phase 3 APOLLO trial, which aims to provide additional data using sunlight exposure as a primary endpoint. The trial is expected to enroll approximately 150 patients, with top-line results anticipated in the fourth quarter of 2026. Following these results, Disc plans to submit a new application for approval, with a potential FDA decision projected for mid-2027.
Market Reaction and Implications
The FDA's decision led to a significant decline in Disc Medicine's stock, which fell by approximately 22%, closing at $49.01. Analysts have noted that while the rejection is a setback, the ongoing APOLLO trial could provide a pathway to eventual approval. The company maintains a robust financial position, reporting approximately $791 million in cash and marketable securities, which supports its operations through 2029.
Criticism and Industry Context
The rejection of bitopertin has drawn attention to broader concerns regarding the FDA's evolving standards for drug approvals, particularly for rare diseases. Industry experts have criticized the agency for its stringent requirements, which they argue may hinder timely access to potentially life-saving therapies. This sentiment was echoed by Biohaven CEO Vlad Coric, who highlighted systemic issues within the FDA that may affect drug approvals for rare conditions.
Verbatim Quotes
- “While our efforts at utilizing expedited pathways to get bitopertin to patients quickly have not come to fruition, we are continuing to pursue all avenues in support of FDA approval,” — John Quisel, CEO of Disc Medicine
- “This lack of correlation between the changes in PPIX and clinical outcomes measured leaves significant uncertainty that bitopertin will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling,” — FDA Letter
The outcome of the APOLLO trial will be pivotal for Disc Medicine as it seeks to navigate the regulatory landscape and address the FDA's concerns regarding bitopertin's efficacy.
